Similar expression profiles in CD34(+) cells from chronic phase chronic myeloid leukemia patients with and without deep molecular responses to nilotinib

The life expectancy of patients with chronic phase chronic myeloid leukemia on tyrosine kinase inhibitor therapy now approaches that of the general population. Approximately 60% of patients treated with second generation tyrosine kinase inhibitors achieve a deep molecular response, the prerequisite...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncotarget
Päätekijät: Patel, Ami B., Lange, Thoralf, Pomicter, Anthony D., Conley, Christopher J., Harrington, Christina A., Reynolds, Kimberly R., Kelley, Todd W., O’Hare, Thomas, Deininger, Michael W.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Impact Journals LLC 2018
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5915162/
https://ncbi.nlm.nih.gov/pubmed/29707154
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24954
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia